MedTrace Logo

The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke

NCT05636748 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2025-12-02

No results posted yet for this study

Summary

Ischaemic stroke is usually due to occlusion of a cerebral artery by thrombus. However, it is often difficult to identify the source of thrombus, or to confirm thrombus as a cause of ischaemic stroke. Moreover, it is debated whether thrombosis plays any role in certain types of stroke such as lacunar stroke. In preliminary studies, the investigators have evaluated a novel clinical grade thrombus-specific radiotracer, 18F-GP1, which has a high specificity for the glycoprotein IIb/IIIa receptor on activated platelets. The investigations have demonstrated that 18F-GP1 is highly sensitive to in vivo thrombus formation and demonstrates avid binding to thrombus associated with myocardial infarction, pulmonary embolism and aortic bioprosthesis. This study will use this imaging approach to define the role and origin of thrombus in patients with ischaemic stroke, cryptogenic stroke and lacunar stroke.The investigators will also assess its added clinical value in assessing patients with ischaemic stroke.

Conditions

Interventions

DIAGNOSTIC_TEST

18F-GP1 PET/CT

Patient will receive 1 18F-GP1 PET/CT

DIAGNOSTIC_TEST

Agitated Contrast Echocardiogram

Agitated saline and ultrasound contrast will be performed to assess for intracardiac shunts and left ventricular thrombus.

DIAGNOSTIC_TEST

MRI Head

Where necessary, if the CT head is normal or the clinical diagnosis of a stroke is not definite, a research MRI head will be undertaken if this has not already been performed as part of standard care.

DIAGNOSTIC_TEST

ECG Monitoring

All patients who do not have evidence of atrial fibrillation or atrial flutter on their 12-lead ECG will undergo an ECG Holter monitor for up to 7 days. This will be part of their standard care. If this has not been arranged by the usual care team this will be performed as a research procedure.

Sponsors & Collaborators

  • British Heart Foundation

    collaborator OTHER

  • University of Edinburgh

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05636748 on ClinicalTrials.gov